Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Hi-View Resources Buys Jim Property in Toodoggone Region in British Columbia

Hi-View Resources Buys Jim Property in Toodoggone Region in British Columbia

MT newswireMT newswire2026/09/16 11:20
07:20 AM EDT, 09/16/2026 (MT Newswires) -- Hi-View Resources (GXLD.CN) bought the Jim Property in the Toodoggone Gold & Copper District of northern British Columbia, it said in a statement on Wednesday. The company acquired 100% interest in the property from an arm's length vendor by issuing 100,000 of its common shares, making a CA$5,000 cash payment, and granting the vendor a 2% net smelter returns royalty (NSR) on the property, of which Hi-View has the right to buy back 1% for CA$1 million, it said. "With a gossanous zone visible at surface, we believe this could indicate hidden sulphide mineralization at depth, possibly associated with a copper porphyry system," said Hi-View CEO R. Nick Horsley. "We see this as a target worth following up on." The company's shares last traded Sept. 14, closing at CA$0.25 on the Canadian Securities Exchange.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar

Deutsche Bank believes that the continuously expanding chip trade surplus in Asia is becoming a supporting force for the US dollar, as related profits are increasingly being reinvested into the US stock market.

智通财经•2026/11/16 23:03
The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar

Roche's (RHHBY.US) new breast cancer drug Wilserdly approved by FDA: Analysts predict peak annual sales could reach up to $14.5 billion

Roche's (RHHBY.US) new oral breast cancer drug has been approved by U.S. regulators, paving the way for this medication, which the pharmaceutical company hopes will transform the treatment of the disease.

智通财经•2026/11/16 22:53